Hughes, Timothy P., Branford, Susan, Cooney, Julian, Leahy, Michael F., Rowlings, Philip, Catalano, John, Hertzberg, Mark, Filshie, Robin, Mills, Anthony K., Fay, Keith, Durrant, Simon, Januszewicz, Henry, White, Deborah L., Joske, David, Underhill, Craig, Dunkley, Scott, Lynch, Kevin, Grigg, Andrew, Reynolds, John, Koelmeyer, Rachel, Seymour, John F., Taylor, Kerry, Arthur, Chris, Schwarer, Anthony K., Morton, James. American Society of Hematology; 2008. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Hertzberg, Mark, Matthews, Jane Palfrey, Abdi, Ehtesham, Green, Michael, Bonaventura, Anthony, Marlton, Paula, Cannell, Paul, Wolf, Max, Stone, Janey Malka, Dubosq, Ming-Celine, Grigg, Andrew, Ellis, David, Benson, Warwick, Browett, Peter, Horvath, Noemi, Januszewicz, Henry. Wiley-Blackwell Publishing Ltd; 2014. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.